Table 1 Comparison of baseline demographics and clinical characteristics of the study patients.
From: Cost of antipsychotic polypharmacy in the treatment of schizophrenia
Variables | OLZ (N = 405) | RIS (N = 276) | QUE (N = 115) | p-value |
|---|---|---|---|---|
Age at Baseline | 41.8(10.5) | 40.4(12.1) | 39.62(10.9) | 0.0826 |
Age of Illness Onset | 19.5(8.3) | 20.0(9.2) | 21.0(9.9) | 0.2516 |
Gender (% Male) | 61.7%(n = 250) | 54.7%(n = 151) | 47.8%(n = 55) | 0.0165 |
Race (%) | 0.2584 | |||
White | 46.7%(n = 189) | 45.3%(n = 125) | 53.9%(n = 62) | |
Black | 41.2%(n = 167) | 36.6%(n = 101) | 33.9%(n = 39) | |
Hispanic | 8.9%(n = 36) | 13.8%(n = 38) | 8.7%(n = 10) | |
Others | 3.2%(n = 13) | 4.4%(n = 12) | 3.5%(n = 4) | |
Insurance (%) | 0.5837 | |||
Medicaid/Medicare | 83.0%(n = 327) | 80.2%(n = 218) | 83.9%(n = 94) | |
Champus/VA | 6.8%(n = 27) | 5.2%(n = 14) | 2.7%(n = 3) | |
Private/HMO | 2.3%(n = 9) | 4.0%(n = 11) | 2.7%(n = 3) | |
Other Insurance | 1.0%(n = 4) | 1.5%(n = 4) | 1.8%(n = 2) | |
No Insurance | 6.8%(n = 27) | 9.2%(n = 25) | 8.9%(n = 10) | |
Marriage Status (% single) | 63.0%(n = 254) | 57.8%(n = 129) | 61.7%(n = 71) | 0.3885 |
Education (% High School or Less) | 71.6%(n = 287) | 63.9%(n = 175) | 67.3%(n = 76) | 0.1046 |
Comorbidity | ||||
Diagnosis of Substance use (%) | 30.9%(n = 125) | 29.4%(n = 81) | 19.1%(n = 22) | 0.0467 |
Diagnosis of Mental Retardation (%) | 7.6%(n = 31) | 6.2%(n = 17) | 8.7%(n = 10) | 0.626 |
Diagnosis of Personality (%) | 18.3%(n = 74) | 13.0%(n = 36) | 20.9%(n = 24) | 0.0925 |
Diagnosis of Borderline (%) | 2.7%(n = 11) | 2.9%(n = 8) | 5.2%(n = 6) | 0.3827 |
Diagnosis of Mental Retardation or Borderline (%) | 10.4%(n = 42) | 8.3%(n = 23) | 13.0%(n = 15) | 0.3529 |
Schizoaffective disorder diagnosis at enrollment (%) | 39.6%(n = 132) | 33.3%(n = 92) | 40%(n = 46) | 0.3239 |
Hospitalization Status on Initiation day (%) | 12.8%(n = 52) | 22.1%(n = 61) | 13.9%(n = 16) | 0.0043 |
MADRS Score at Enrollment | 15.6(10.3) | 15.5(11.4) | 16.3(11.4) | 0.8006 |
PANSS Total at Enrollment | 73.2(18.4) | 72.9(18.9) | 73.6(17.74) | 0.9451 |
Total days on index drug post 1 year after initiation | 280(121) | 260(134) | 239(136) | 0.0048 |
Total days CONTINUOUSLY on index drug post 1-year after initiation | 272(129) | 250(1431) | 225(147) | 0.0023 |